FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 320:1592-1597 June 15, 1989 Number 24 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

We performed a randomized, double-blind, controlled six-month trial of prednisone in 103 boys with Duchenne's muscular dystrophy (age, 5 to 15 years). The patients were assigned to one of three regimens: prednisone, 0.75 mg per kilogram of body weight per day (n = 33); prednisone, 1.5 mg per kilogram per day (n = 34); or placebo (n = 36). The groups were initially comparable in all measures of muscle function. Both prednisone groups had significant improvement of similar degree in the summary scores of muscle strength and function. Improvement began as early as one month and peaked by three months. At six months the high-dose prednisone group, as compared with the placebo group, had improvement in the time needed to rise from a supine to a standing position (3.4 vs. 6.2 seconds), to walk 9 m (7.0 vs. 9.7 seconds), and to climb four stairs (4.0 vs. 7.1 seconds), in lifting a weight (2.1 vs. 1.2 kg), and in forced vital capacity (1.7 vs. 1.5 liters) (P less than 0.001 for all comparisons). There was an increase in urinary creatinine excretion (261 vs. 190 mg per 24 hours), which suggested an increase in total muscle mass. However, the prednisone-treated patients who had required long-leg braces (n = 5) or wheelchairs (n = 11) continued to require them. The most frequent side effects were weight gain, cushingoid appearance, and excessive hair growth. We conclude from this six-month study that prednisone improves the strength and function of patients with Duchenne's muscular dystrophy. However, further research is required to identify the mechanisms responsible for these improvements and to determine whether prolonged treatment with corticosteroids may be warranted despite their side effects.

Source Information

Department of Neurology, Ohio State University College of Medicine, Columbus.

This article has been cited by other articles:

• Kota, J., Handy, C. R., Haidet, A. M., Montgomery, C. L., Eagle, A., Rodino-Klapac, L. R., Tucker, D., Shilling, C. J., Therlfall, W. R., Walker, C. M., Weisbrode, S. E., Janssen, P. M. L., Clark, K. R., Sahenk, Z., Mendell, J. R., Kaspar, B. K. (2009). Follistatin Gene Delivery Enhances Muscle Growth and Strength in Nonhuman Primates. Sci Transl Med 1: 6ra15-6ra15 [Abstract] [Full Text]  
• Van den Berg-Vos, R. M., Visser, J., Kalmijn, S., Fischer, K., de Visser, M., de Jong, V., de Haan, R. J., Franssen, H., Wokke, J. H. J., Van den Berg, L. H. (2009). A Long-term Prospective Study of the Natural Course of Sporadic Adult-Onset Lower Motor Neuron Syndromes. Arch Neurol 66: 751-757 [Abstract] [Full Text]  
• Rodino-Klapac, L. R., Lee, J-S, Mulligan, R. C., Clark, K. R., Mendell, J. R. (2008). Lack of toxicity of alpha-sarcoglycan overexpression supports clinical gene transfer trial in LGMD2D. Neurology 71: 240-247 [Abstract] [Full Text]  
• Rosales, X. Q., Chu, M.-L., Shilling, C., Wall, C., Pastores, G. M., Mendell, J. R. (2008). Fidelity of Gamma-Glutamyl Transferase (GGT) in Differentiating Skeletal Muscle From Liver Damage. J Child Neurol 23: 748-751 [Abstract]  
• Rodino-Klapac, L. R., Chicoine, L. G., Kaspar, B. K., Mendell, J. R. (2007). Gene Therapy for Duchenne Muscular Dystrophy: Expectations and Challenges. Arch Neurol 64: 1236-1241 [Abstract] [Full Text]  
• Yamaguchi, Y., Nagase, T., Tomita, T., Nakamura, K., Fukuhara, S., Amano, T., Yamamoto, H., Ide, Y., Suzuki, M., Teramoto, S., Asano, T., Kangawa, K., Nakagata, N., Ouchi, Y., Kurihara, H. (2007). beta-Defensin overexpression induces progressive muscle degeneration in mice. Am. J. Physiol. Cell Physiol. 292: C2141-C2149 [Abstract] [Full Text]  
• King, W. M., Ruttencutter, R., Nagaraja, H. N., Matkovic, V., Landoll, J., Hoyle, C., Mendell, J. R., Kissel, J. T. (2007). Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 68: 1607-1613 [Abstract] [Full Text]  
• Visser, J., van den Berg-Vos, R. M., Franssen, H., van den Berg, L. H., Wokke, J. H., Vianney de Jong, J. M., Holman, R., de Haan, R. J., de Visser, M. (2007). Disease Course and Prognostic Factors of Progressive Muscular Atrophy. Arch Neurol 64: 522-528 [Abstract] [Full Text]  
• Lovering, R. M, Porter, N. C, Bloch, R. J (2005). The Muscular Dystrophies: From Genes to Therapies. ptjournal 85: 1372-1388 [Abstract] [Full Text]  
• Hirtz, D., Iannaccone, S., Heemskerk, J., Gwinn-Hardy, K., Moxley, R. III, Rowland, L. P. (2005). Challenges and opportunities in clinical trials for spinal muscular atrophy. Neurology 65: 1352-1357 [Abstract] [Full Text]  
• Chakkalakal, J. V., Thompson, J., Parks, R. J., Jasmin, B. J. (2005). Molecular, cellular, and pharmacological therapies for Duchenne/Becker muscular dystrophies. FASEB J. 19: 880-891 [Abstract] [Full Text]  
• Griggs, R. C., Bushby, K. (2005). Continued need for caution in the diagnosis of Duchenne muscular dystrophy. Neurology 64: 1498-1499 [Full Text]  
• Moxley, R. T. III, Ashwal, S., Pandya, S., Connolly, A., Florence, J., Mathews, K., Baumbach, L., McDonald, C., Sussman, M., Wade, C. (2005). Practice Parameter: Corticosteroid treatment of Duchenne dystrophy: Report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 64: 13-20 [Abstract] [Full Text]  
• Beenakker, E. A. C., Fock, J. M., Van Tol, M. J., Maurits, N. M., Koopman, H. M., Brouwer, O. F., Van der Hoeven, J. H. (2005). Intermittent Prednisone Therapy in Duchenne Muscular Dystrophy: A Randomized Controlled Trial. Arch Neurol 62: 128-132 [Abstract] [Full Text]  
• (2004). Respiratory Care of the Patient with Duchenne Muscular Dystrophy: ATS Consensus Statement. Am. J. Respir. Crit. Care Med. 170: 456-465 [Full Text]  
• Tarnopolsky, M. A., Mahoney, D. J., Vajsar, J., Rodriguez, C., Doherty, T. J., Roy, B. D., Biggar, D. (2004). Creatine monohydrate enhances strength and body composition in Duchenne muscular dystrophy. Neurology 62: 1771-1777 [Abstract] [Full Text]  
• Alman, B. A., Raza, S. N., Biggar, W. D. (2004). Steroid Treatment and the Development of Scoliosis in Males with Duchenne Muscular Dystrophy. JBJS 86: 519-524 [Abstract] [Full Text]  
• Van den Berg-Vos, R. M., Visser, J., Franssen, H., de Visser, M., de Jong, J. M. B. V., Kalmijn, S., Wokke, J. H. J., Van den Berg, L. H. (2003). Sporadic lower motor neuron disease with adult onset: classification of subtypes. Brain 126: 1036-1047 [Abstract] [Full Text]  
• Wong, B. L. Y., Christopher, C. (2002). Corticosteroids in Duchenne Muscular Dystrophy: A Reappraisal. J Child Neurol 17: 183-190 [Abstract]  
• Johnsen, S. D., Clinic, B. B. (2001). Prednisone Therapy in Becker's Muscular Dystrophy. J Child Neurol 16: 870-871 [Abstract]  
• Fenichel, G. M., Griggs, R. C., Kissel, J., Kramer, T. I., Mendell, J. R., Moxley, R. T., Pestronk, A., Sheng, K., Florence, J., King, W. M., Pandya, S., Robison, V. D., Wang, H. (2001). A randomized efficacy and safety trial of oxandrolone in the treatment of Duchenne dystrophy. Neurology 56: 1075-1079 [Abstract] [Full Text]  
• Periquet, M. I., Novak, V., Collins, M. P., Nagaraja, H. N., Erdem, S., Nash, S. M., Freimer, M. L., Sahenk, Z., Kissel, J. T., Mendell, J. R. (1999). Painful sensory neuropathy: Prospective evaluation using skin biopsy. Neurology 53: 1641-1641 [Abstract] [Full Text]  
• VIGNOS, P. J. JR., WAGNER, M. B., KARLINCHAK, B., KATIRJI, B. (1996). Evaluation of a Program for Long-Term Treatment of Duchenne Muscular Dystrophy. Experience at the University Hospitals of Cleveland. JBJS 78: 1844-52 [Abstract] [Full Text]  
• Mendell, J. R., Kissel, J. T., Amato, A. A., King, W., Signore, L., Prior, T. W., Sahenk, Z., Benson, S., McAndrew, P. E., Rice, R., Nagaraja, H., Stephens, R., Lantry, L., Morris, G. E., Burghes, A. H.M. (1995). Myoblast Transfer in the Treatment of Duchenne's Muscular Dystrophy. NEJM 333: 832-838 [Abstract] [Full Text]  
• Tan, E., Lynn, D. J., Amato, A. A., Kissel, J. T., Rammohan, K. W., Sahenk, Z., Warmolts, J. R., Jackson, C. E., Barohn, R. J., Mendell, J. R. (1994). Immunosuppressive Treatment of Motor Neuron Syndromes: Attempts to Distinguish a Treatable Disorder. Arch Neurol 51: 194-200 [Abstract]  
• Bach, J. R. (1992). Perspectives, Indications, and the Ethics of Prolonging "Meaningful Life" for Individuals with Progressive Neuromuscular Disease. Neurorehabil Neural Repair 6: 61-66  
• Fenichel, G. M., Mendell, J. R., Moxley, R. T. III, Griggs, R. C., Brooke, M. H., Miller, J. P., Pestronk, A., Robison, J., King, W., Signore, L., Pandya, S., Florence, J., Schierbecker, J., Wilson, B. (1991). A Comparison of Daily and Alternate-Day Prednisone Therapy in the Treatment of Duchenne Muscular Dystrophy. Arch Neurol 48: 575-579 [Abstract]  
• Griggs, R. C., Moxley, R. T. III, Mendell, J. R., Fenichel, G. M., Brooke, M. H., Pestronk, A., Miller, J. P., the Clinical Investigation of Duchenne Dystrophy G, (1991). Prednisone in Duchenne Dystrophy: A Randomized, Controlled Trial Defining the Time Course and Dose Response. Arch Neurol 48: 383-388 [Abstract]